Posted in | News

Hollysys Automation Technologies Signs Contract to Provide High-Speed Rail ATP Equipment

Hollysys Automation Technologies has signed an agreement with the Ministry of Railways of China ("MOR") to provide its 200-250km/h high-speed rail ATP (Automatic Train Protection) equipment. Delivery will be completed by December, 2011. The high-speed rail ATP equipment contract is valued at approximately RMB 26.60 million or US$ 4.2 million.

The on-board communication equipment ATP operates along with the ground-based communication equipment TCC (Train Control Center) as the vital control components in the high-speed railway communication systems. They guarantee the reliability and safety of the high-speed railway operation.

Hollysys, a leading supplier of automation and control technologies, has its presence in more than 40 cities in China and has offices and subsidiaries in India, Dubai, Malaysia and Singapore. It offers its services to more than 2,000 customers in the railway, industrial and subway & nuclear businesses in China, the middle east and the south-east Asia.

Dr. Changli Wang, Hollysys’ CEO and Chairman, stated that the company is happy to sign the high-speed rail ATP contract with MOR for the works that are already completed in large. He also said that currently, almost 17,000 km of high-speed rail tracks are under construction in China, and there is an immense market growth in high-speed rail signaling market for Hollysys. The entire product suite of the company’s established high-speed rail signaling systems obtained European Safety Standard certification.

Source: http://www.hollysys.com.sg/home/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 22). Hollysys Automation Technologies Signs Contract to Provide High-Speed Rail ATP Equipment. AZoBuild. Retrieved on November 22, 2024 from https://www.azobuild.com/news.aspx?newsID=14718.

  • MLA

    Scanlon, Joel. "Hollysys Automation Technologies Signs Contract to Provide High-Speed Rail ATP Equipment". AZoBuild. 22 November 2024. <https://www.azobuild.com/news.aspx?newsID=14718>.

  • Chicago

    Scanlon, Joel. "Hollysys Automation Technologies Signs Contract to Provide High-Speed Rail ATP Equipment". AZoBuild. https://www.azobuild.com/news.aspx?newsID=14718. (accessed November 22, 2024).

  • Harvard

    Scanlon, Joel. 2019. Hollysys Automation Technologies Signs Contract to Provide High-Speed Rail ATP Equipment. AZoBuild, viewed 22 November 2024, https://www.azobuild.com/news.aspx?newsID=14718.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.